Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial
Name
415_2020_9845_ReferencePDF.pdf
Size
326.9 KB
Format
Adobe PDF
Checksum (MD5)
bbe8eae53a82a9005b8ccab8d37f8b8c
Author(s)
Mateen, Farrah J
Vogel, Andre C
Kaplan, Tamara B
Hotan, Gladia C
Grundy, Sara J
Holroyd, Kathryn B
Manalo, Natalie
Stauder, Matthew
Videnovic, Aleksandar
Date Issued
April 24, 2020
Publisher
Springer Berlin Heidelberg
Version
Author's final manuscript
Abstract
Abstract
Background
Bright white light therapy (LT) can improve fatigue in several disease states but has not been studied in multiple sclerosis (MS).
Objective
To determine whether controlled home-based LT is feasible, tolerable, and well-adhered to in MS-associated fatigue.
Methods
A randomized, controlled trial of twice-daily 1-h bright white LT (BWLT) (10,000 lx, active arm) versus dim red LT (DRLT) (< 300 lx, control arm) was performed. Adults with MS-associated fatigue were enrolled for 10 weeks: 2-week baseline, 4-week intervention, 4-week washout.
Results
41 participants were enrolled; 35 were randomized (average age 42 years, 80% female; BWLT n = 20; DRLT n = 15). 31 were in the intention to treat analysis. The average duration of LT sessions was similar between groups (BWLT 60.9 min, DRLT 61.5 min, p = 0.70). The most commonly reported adverse event was headache. There were no events that led to discontinuation. Baseline fatigue was severe in both arms (each 53/63 points on the Fatigue Severity Scale (FSS), p = 0.92). FSS was lower following BWLT (FSS 45.8 post-LT, p = 0.04; 44.9 post-washout, p = 0.02 intra-group compared to baseline FSS) and DRLT (FSS 46.7 post-LT, p = 0.03; 43.9 post-washout, p = 0.002 intragroup compared to baseline FSS). There was no difference between BWLT and DRLT groups in the magnitude of reduction of FSS scores (p = 0.81 after LT; p = 0.77 after washout for between group comparisons). Similarly, MS quality of life metrics improved in both arms but were not significantly different between groups after LT (p = 0.22) or washout.
Conclusions
LT is safe, feasible, and well-tolerated in people with MS-associated fatigue. Improvement in both light spectra likely indicates a strong placebo effect for the DRLT group.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s00415-020-09845-w
